Sugi Predict

Sugi Predict / Compounds / SCHEMBL338485

SCHEMBL338485

SCHEMBL338485

N#Cc1cc(N)ncc1Br

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.46
▸ KDR P35968 2/20 0.42
▸ ABL1 P00519 1/20 0.42
▸ MBOAT4 Q96T53 1/20 0.39
▸ CSNK1A1 P48729 1/20 0.37
▸ CLK4 Q9HAZ1 1/20 0.37
▸ ALOX5AP P20292 3/20 0.36
▸ FEN1 P39748 3/20 0.36
▸ PIK3CA P42336 1/20 0.36
▸ PIK3CD O00329 1/20 0.36
▸ NOS3 P29474 2/20 0.35
▸ NOS1 P29475 2/20 0.35
▸ NOS2 P35228 2/20 0.35
▸ GRM4 Q14833 1/20 0.35
▸ KMT2A Q03164 1/20 0.34
▸ PDPK1 O15530 1/20 0.33
▸ GRM6 O15303 1/20 0.33
▸ GRIA1 P42261 1/20 0.33
▸ GRIA2 P42262 1/20 0.33
▸ GRIA3 P42263 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30868505 1.00 HTT (0.46) HTTKDRABL1MBOAT4CSNK1A1
SCHEMBL30294157 0.83 KDR (0.46) HTTKDRABL1CSNK1A1CLK4
SCHEMBL28700799 0.83 KDR (0.46) HTTKDRABL1CSNK1A1CLK4
SCHEMBL16668748 0.80 CSNK1A1 (0.45) HTTKDRABL1MBOAT4CSNK1A1
SCHEMBL30907634 0.80 PDPK1 (0.40) HTTKDRABL1MBOAT4CSNK1A1
SCHEMBL11486802 0.78 PIK3CD (0.42) HTTKDRABL1CSNK1A1CLK4
SCHEMBL23908930 0.75 XDH (0.39) HTTKDRABL1CSNK1A1CLK4
SCHEMBL20157281 0.75 MEN1 (0.39) HTTKDRABL1MBOAT4GRM4
SCHEMBL18031200 0.75 NOS3 (0.56) MBOAT4CSNK1A1CLK4PIK3CAPIK3CD
SCHEMBL1815383 0.75 XDH (0.40) HTTKDRABL1CSNK1A1CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340551-A1 SMALL MOLECULE MODULATORS OF STAT6 GILEAD SCIENCES INC (US) 2025-11-06 — — US disclosed
US-20250325677-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-23 — — US disclosed
EP-4612151-A1 PREPARATION OF IMIDAZOPYRIDINE AND IMIDAZOPYRIDAZINE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS Merck Sharp & Dohme LLC (US) 2025-09-10 — — EP disclosed
EP-4585596-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF Shanghai Yingli Pharmaceutical Co., Ltd (CN) 2025-07-16 — — EP disclosed
US-20240158408-A1 Nitrogen-Containing Heterocyclic Compound, Pharmaceutical Compositions thereof and Use thereof 280 BIO, INC. (US) 2024-05-16 — — US disclosed
WO-2024097573-A1 PREPARATION OF IMIDAZOPYRIDINE AND IMIDAZOPYRIDAZINE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS MERCK SHARP & DOHME LLC (US) 2024-05-10 — — WO disclosed
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-01-25 — — US disclosed
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-01-25 — — US disclosed
US-20230303569-A1 HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS ARISAN THERAPEUTICS INC. (US) 2023-09-28 — — US disclosed
US-20230303569-A1 HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS ARISAN THERAPEUTICS INC. (US) 2023-09-28 — — US disclosed
US-20100249126-A1 PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) 2010-09-30 — — US disclosed
US-20100249126-A1 PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) 2010-09-30 — — US disclosed
EP-1984350-B1 PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS NOVARTIS AG (CH) 2010-08-18 — — EP disclosed
US-20090253689-A1 Organic Compounds NOVARTIS AG (CH) 2009-10-08 — — US disclosed
US-20090253689-A1 Organic Compounds NOVARTIS AG (CH) 2009-10-08 — — US disclosed
EP-2004643-A1 ORGANIC COMPOUNDS Novartis AG (CH) 2008-12-24 — — EP disclosed
EP-1984350-A1 PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS Novartis AG (CH) 2008-10-29 — — EP disclosed
WO-2007113226-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2007-10-11 — — WO disclosed
WO-2007113226-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2007-10-11 — — WO disclosed
WO-2007084786-A1 PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS NOVARTIS AG (CH) 2007-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158408-A1 Nitrogen-Containing Heterocyclic Compound, Pharmaceutical Compositions thereof and Use thereof MTOR, AKT1, AKT2 HTT 186/4885KDR 2620/4885ABL1 417/4885
US-20250325677-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 HTT 1112/4885KDR 829/4885ABL1 342/4885
US-20230303569-A1 HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS C3AR1, C9, C1R HTT 358/4885KDR 1105/4885ABL1 169/4885
US-20250340551-A1 SMALL MOLECULE MODULATORS OF STAT6 STAT6, STAT1, STAT5B HTT 2728/4885KDR 971/4885ABL1 252/4885
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF PDXK, HIPK1, PCK1 HTT 1147/4885KDR 4387/4885ABL1 2586/4885
US-20100249126-A1 PYRIMIDINE DERIVATIVES USED AS PI-3-KINASE INHIBITORS PIK3CA, PI4KA, PI4KB HTT 4458/4885KDR 734/4885ABL1 390/4885
US-20090253689-A1 Organic Compounds OAT, GPR119, OTC HTT 3260/4885KDR 3065/4885ABL1 3439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.